Can Biomarkers Help the Early Diagnosis of Parkinson’s Disease?

被引:0
作者
Weidong Le
Jie Dong
Song Li
Amos D. Korczyn
机构
[1] Dalian Medical University,Liaoning Provincial Center for Clinical Research on Neurological Diseases, The First Affiliated Hospital
[2] Dalian Medical University,Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital
[3] Dalian Medical University,Collaborative Innovation Center for Brain Science, The First Affiliated Hospital
[4] Tel Aviv University,Department of Neurology, Sackler School of Medicine
来源
Neuroscience Bulletin | 2017年 / 33卷
关键词
Parkinson’s disease; Biomarker; Early diagnosis; Molecular imaging; Biochemical markers;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease (PD) is a complex neurodegenerative disease with progressive loss of dopamine neurons. PD patients usually manifest a series of motor and non-motor symptoms. In order to provide better early diagnosis and subsequent disease-modifying therapies for PD patients, there is an urgent need to identify sensitive and specific biomarkers. Biomarkers can be divided into four categories: clinical, imaging, biochemical, and genetic. Ideal biomarkers not only improve our understanding of PD pathogenesis and progression, but also provide benefits for early risk evaluation and clinical diagnosis of PD. Although many efforts have been made and several biomarkers have been extensively investigated, few if any have been found useful for early diagnosis. Here, we summarize recent developments in the discovered biomarkers of PD and discuss their merits and limitations for the early diagnosis of PD.
引用
收藏
页码:535 / 542
页数:7
相关论文
共 405 条
[1]  
Kordower JH(2013)Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease Brain 136 2419-2431
[2]  
Olanow CW(2015)MDS research criteria for prodromal Parkinson’s disease Mov Disord 30 1600-1611
[3]  
Dodiya HB(2014)Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson’s disease Mov Disord 29 454-462
[4]  
Chu Y(2008)Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy Neurology 71 1796-1803
[5]  
Beach TG(2011)Preclinical biomarkers of Parkinson disease Arch Neurol 68 22-30
[6]  
Adler CH(2004)Biomarkers of neurodegenerative disorders: how good are they? Cell Res 14 347-358
[7]  
Berg D(2015)Can the disease course in Parkinson’s disease be slowed? BMC Med 13 295-292
[8]  
Postuma RB(2010)Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy EPMA J 1 273-108
[9]  
Adler CH(2013)The PRIPS study: screening battery for subjects at risk for Parkinson’s disease Eur J Neurol 20 102-772
[10]  
Bloem BR(2014)Prodromal features for Parkinson’s disease - baseline data from the TREND study Eur J Neurol 21 766-1746